

FOI 2714

20th November 2024

FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST

How many Non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:

- ALK Inhibitors (Alectinib - 4, Brigatinib - 0, Ceritinib - 0, Crizotinib - 1, Lorlatinib - 1)
- Amivantamab - 0
- Atezolizumab Monotherapy - 5
- Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel - 0
- Atezolizumab subcutaneous - 0
- Dabrafenib + Trametinib - 0
- Docetaxel monotherapy or in combination with Carboplatin/Cisplatin - 3
- Durvalumab - 5
- Gemcitabine - 1
- Nintedanib + Docetaxel - 1
- Nivolumab - 1
- Osimertinib - 10
- Other EGFR Inhibitors (Afatinib - 0, Erlotinib - 1, Gefitinib - 0, Dacomitinib - 0, Mobocertinib - 1)
- Paclitaxel - 8 (in combination with carboplatin)
- Pembrolizumab Monotherapy - 12
- Pembrolizumab + Paclitaxel + Platinum (Carboplatin/Cisplatin) - 0
- Pembrolizumab + Pemetrexed + Platinum (Carboplatin/Cisplatin) - 3
- Pemetrexed + Platinum (Carboplatin/Cisplatin) - 4
- RET Inhibitors (Pralsetinib, Selpercatinib) - 0
- Sotorasib - 2
- Tepotinib - 0
- Vinorelbine monotherapy or in combination with Carboplatin/Cisplatin - 0
- Other active systemic anti-cancer therapy - 0
- Palliative care only – information not centrally held

Email: Foi.Team@Southerntrust.hscni.net